Showing 1 - 20 results of 60 for search '"oncogene"', query time: 0.05s Refine Results
  1. 1
  2. 2

    Oncogenic PIK3CA corrupts growth factor signaling specificity by Ralitsa R Madsen, Alix Le Marois, Oliwia N Mruk, Margaritis Voliotis, Shaozhen Yin, Jahangir Sufi, Xiao Qin, Salome J Zhao, Julia Gorczynska, Daniele Morelli, Lindsay Davidson, Erik Sahai, Viktor I Korolchuk, Christopher J Tape, Bart Vanhaesebroeck

    Published 2024-12-01
    “…Using this framework, we found that the PIK3CA H1047R oncogene was not a simple, constitutive activator of the pathway as often presented. …”
    Get full text
    Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    PTOV1 exerts pro-oncogenic role in colorectal cancer by modulating SQSTM1-mediated autophagic degradation of p53 by Yongli Fan, Yuqin Li, Xia Luo, Shiqi Xiang, Jia Hu, Jingchun Zhan, Weilong Chang, Rui Deng, Xianwen Ran, Yize Zhang, Yudie Cai, Weiwei Zhu, Huifen Wang, Zhibo Liu, Di Wang

    Published 2025-02-01
    “…Conclusion Our study unveils the oncogenic role of PTOV1 in CRC progression, which was achieved by promoting SQSTM1 directed autophagic degradation of p53. …”
    Get full text
    Article
  10. 10

    Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report by Carolin Seeling, Sonja Dahlum, Ralf Marienfeld, Vera Jan, Brigitte Rack, Uwe Gerstenmaier, Ambros J. Beer, Regine Mayer-Steinacker, Wolfgang Thaiss, Thomas F. E. Barth, Thomas Seufferlein, Nadine T. Gaisa, Stephan Stilgenbauer, Wolfgang Janni, Reiner Siebert, Hartmut Döhner, Verena I. Gaidzik

    Published 2025-01-01
    “…Conclusions In the era of accessible and comprehensive genetic and phenotypic tumor profiling, this case study of a patient with Li-Fraumeni syndrome underscores the success of precision oncology in harnessing additional somatic oncogenic driver alterations. Furthermore, it emphasizes the indispensable role of an interdisciplinary molecular tumor board, enhancing the awareness of molecular profiling and targeted therapies in patients with rare cancer susceptibility disorders.…”
    Get full text
    Article
  11. 11
  12. 12
  13. 13
  14. 14

    Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis by Mariana M. Sebastião, Rodrigo S. Ho, João Paulo V. de Carvalho, Micha Nussbaum

    Published 2020-09-01
    “…The aim of the study was to carry out a systematic review and a meta-analysis in order to determine the accuracy of NGS of ctDNA to detect six oncogenic driver alterations: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1); serine/threonine-protein kinase B-RAF (BRAF); RET proto-oncogene (RET); and MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 in patients with aNSCLC. …”
    Get full text
    Article
  15. 15

    Melanoma genomics – will we go beyond BRAF in clinics? by Justyna Mirek, Wiesław Bal, Magdalena Olbryt

    Published 2024-09-01
    “…However, evaluating the oncogene BRAF mutation in codon V600 is still the only companion diagnostic genomic test commonly implemented in clinics for molecularly targeted treatment of advanced melanoma. …”
    Get full text
    Article
  16. 16

    Natural products as anticancer agents and enhancing their efficacy by a mechanism-based precision approach by Stephen Safe

    Published 2024-07-01
    “…In this review, I have discussed a limited number of targets including non-oncogene addiction genes such as Sp transcription factors, reactive oxygen species (ROS) or the orphan nuclear receptor 4A (NR4A) sub-family. …”
    Get full text
    Article
  17. 17

    Inhibition of lanosterol synthase linking with MAPK/JNK signaling pathway suppresses endometrial cancer by Liangjian Ma, Wunan Huang, Xiaolei Liang, Hongli Li, Wei Yu, Lexin Liu, Yuelin Guan, Chang Liu, Xiangjun Chen, Lidan Hu

    Published 2025-02-01
    “…These findings establish LSS as a novel oncogene in EC, promoting tumor progression through MAPK/JNK signaling activation and cholesterol ester accumulation, and highlight the therapeutic potential of targeting LSS in EC treatment.…”
    Get full text
    Article
  18. 18

    Distinct roles of Constitutive Photomorphogenesis Protein 1 homolog (COP1) in human hepatocyte models by Sébastien Soubeyrand, Paulina Lau, Ruth McPherson, Ruth McPherson

    Published 2025-02-01
    “…Prior work in hepatocyte-derived tumors categorized COP1 as an oncogene, but its role in untransformed hepatocytes remains largely unexplored. …”
    Get full text
    Article
  19. 19

    A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022 by TAN Meijuan, YANG Shijie, XU Xiequn

    Published 2024-07-01
    “…The key areas of focus in highly cited literature were RET proto oncogene, targeted therapy, RET gene mutation, and so on.ConclusionsIn the past 20 years, MTC related research has shown a gradual upward trend, with developed countries led by the United States taking a leading position in this field. …”
    Get full text
    Article
  20. 20

    Nrf2/cyclooxygenase 2 signaling in Cr(VI)-induced carcinogenesis by Lei Zhao, Yi-Fang Wang, Andrea Adamcakova-Dodd, Peter S. Thorne, Ranakul Islam, Ke Jian Liu, Fei Chen, Jia Luo, Ling-Zhi Liu

    Published 2025-02-01
    “…In summary, our study revealed the oncogenic role of COX-2 and identified two novel regulatory mechanisms for COX-2 overexpression in Cr(VI)-induced carcinogenesis.…”
    Get full text
    Article